FDA's Susan Alpert
This article was originally published in The Gray Sheet
Executive SummaryBecomes permanent director of the Center for Devices and Radiological Health's Office of Device Evaluation, CDRH Director Bruce Burlington announces Aug. 11. Alpert, who has served as ODE acting director since last August ("The Gray Sheet" Aug. 30, 1993, p. 2), is praised by Burlington as "an outstanding manager and advocate for ODE's program and its people"
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.